Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for persistent microalbuminuria over 24 weeks
NL-OMON50643Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in albuminuria, chronic kidney disease (CKD), sponsored by University Medical Center Groningen. Started Feb 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
albuminuriachronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON50643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50643.